PURPOSE: To evaluate the feasibility of discontinuing treatment with mirabegron once symptoms have subsided in patients with overactive bladder (OAB). METHODS: The present study evaluated a total of 159 female OAB patients (age 62.9 ± 12.36), each of which were prescribed 50 mg/day mirabegron (Time point 1-T1). Data obtained from voiding diaries and patient-reported outcome variables were assessed during follow-up visits at months 1, 3, 6, 12, 18 (T2), and 21 (T4). At the 18-month visit, patients with an Urgency Bother-Visual Analog Scale score of ≤ 50% were advised to stop treatment with mirabegron. Upon re-emergence or worsening of OAB symptoms, patients were allowed to start taking medication again at their discretion (T3). Statistical analysis was performed using a Chi-square test. An ANOVA analysis and a two-sample t test were used to evaluate differences between groups. RESULTS: A total of 56 out of 159 (35.3%) patients took 50 mg of mirabegron daily between T1 and T2. A total of 17 out of 56 patients (30.4%) did not meet the criteria for mirabegron discontinuation (Group A). A total of 24 out of 56 patients (42.9%) stopped taking the medication temporarily, but later returned to treatment (Group B). The average time span between T2 and T3 was 53.9 days. Fifteen of 56 patients (26.8%) ceased treatment with mirabegron without starting it again before T4 (Group C). The average time span between T2 and T4, in Group C, was 124.7 days. CONCLUSION: A small percentage of OAB patients were able to discontinue mirabegron due to symptom cessation.

Department of Obstetrics and Gynecology 1 st Medical Faculty Charles University and General Faculty Hospital Prague Czech Republic

Department of Surgical Studies Ostrava University Ostrava Czech Republic

Department of Urology 1 st Medical Faculty Charles University and General Faculty Hospital Prague Czech Republic

Department of Urology and Biomedical Laboratory University of Southern Denmark Odense Denmark

Department of Urology Thomayer's Hospital Prague Czech Republic

Department of Urology University Hospital 17 listopadu 1790 Poruba 708 52 Ostrava Czech Republic

GONA Urogynecological Office Prague Czech Republic

Zobrazit více v PubMed

Int Urogynecol J. 2012 Nov;23(11):1577-80 PubMed

BJU Int. 2011 Oct;108(7):1132-8 PubMed

BJU Int. 2010 May;105(9):1276-82 PubMed

Neurourol Urodyn. 2015 Mar;34(3):255-63 PubMed

Acta Obstet Gynecol Scand. 2013 Oct;92(10):1208-15 PubMed

BJU Int. 2008 Jun;101(11):1388-95 PubMed

Obstet Gynecol Sci. 2015 Nov;58(6):507-13 PubMed

Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5 PubMed

Curr Opin Urol. 2007 Jul;17(4):231-6 PubMed

Curr Opin Obstet Gynecol. 2008 Oct;20(5):489-95 PubMed

Int Neurourol J. 2011 Mar;15(1):48-54 PubMed

Eur Urol. 2008 Sep;54(3):543-62 PubMed

Neurourol Urodyn. 2009;28(4):287 PubMed

BJU Int. 2010 Mar;105(6):832-6 PubMed

Urol Int. 2009;83(2):125-33 PubMed

J Manag Care Pharm. 2009 Nov-Dec;15(9):728-40 PubMed

Eur Urol. 2013 Feb;63(2):283-95 PubMed

Eur Urol. 2006 Jun;49(6):1079-86 PubMed

Neurourol Urodyn. 2011 Apr;30(4):495-502 PubMed

Urology. 2015 Apr;85(4):786-90 PubMed

Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9 PubMed

BJU Int. 2009 Oct;104(7):948-53 PubMed

Int Urogynecol J. 2017 Jul;28(7):1033-1039 PubMed

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations